Research led by Prasad S. Adusumilli focuses on investigation of the tumor immune microenvironment and the development of T-cell‒mediated immunotherapy for thoracic malignancies and pleural-based diseases. His team has championed regional immunotherapy delivery strategies, resulting in translation of mesothelin-targeted CAR T-cell immunotherapy for malignant pleural mesothelioma, lung, and breast cancers.
Pictured: Image from the cover of Journal of Clinical Investigation, August 2016
Prasad S. Adusumilli, MD
Deputy Chief and Attending, Thoracic Service; Vice Chair for Translational Research, Department of Surgery; Co-Director, Mesothelioma Program; Head, Solid Tumors Cell Therapy, Cellular Therapeutics Center
Research FocusPhysician-scientist Prasad S. Adusumilli studies tumor immunology and the development of T-cell‒mediated immunotherapy for thoracic malignancies and pleural-based diseases.
- Grosser R, Cherkassky L, Chintala NK, Adusumilli PS. Combination immunotherapy with CAR T cells and checkpoint blockade for the treatment of solid tumors. Cancer Cell. 2019;36(5):471-82.
- Cherkassky L, Morello A, Villena-Vargas J, Feng Y, Dimitrov DS, Jones DR, Sadelain M, Adusumilli PS. Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition. J Clin Invest. 2016;126(8):3130-44.